Entries by SM

$KPTI positive results from phase 2/3

Micro cap Karyopharm Therapeutics (KPTI) announced positive results from its Phase 2/3 clinical trial, SEAL, assessing selinexor ((KPT-330)) in patients with previously treated, advanced, unresectable, dedifferentiated liposarcoma. Read the full brief in our Daily Pharma Scoop at SeekingAlpha Marketplace.

Is $ADHD worth betting on?

The Alcobra (ADHD) article in Seeking Alpha broadly says that though Alcobra is a company with a failed drug and no future prospects, it has a lot of cash and is selling below its NCAV or net current asset value.  Read our full take in our SeekingAlpha Marketplace Daily Pharma Scoop.

$ICPT buy opportunity for risk prone investors

Our daily analysis of a stock with a major event/upside: Intercept’s Letter Overblown Intercept (ICPT) saw a major slump last week, falling 20% from $110 to $85 or so, after the company’s CEO Dr Mark Pruzanski sent a “Dear Doctor” letter out to prescribing physicians of its Ocaliva medication telling them not to prescribe the […]

$ALNY Phase 3 meets end point; Gets Analysts’ love

Alnylam Pharmaceuticals (ALNY) successfully completed a Phase 3 clinical trial, APOLLO, assessing RNAi therapeutic Patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy, and met its primary endpoint. Gets Analyst love: Analyst Action Rating Target Cowen and Company Reiterates Outperform $93.00 -> $117.00 JMP Securities Raises Target Outperform $101.00 -> $128.00 Needham & Company LLC […]

Morgan Stanley downgrades $AGN

Citigroup reiterates buy on Allergan PLC. (AGN) with target of $280, while Morgan Stanley downgrades AGN from overweight to equal weight, revising target from $284 to $228. Could impact the share price. Check out more ratings on our SeekingAlpha Marketplace Daily Pharma Scoop.

$GEMP gemcabene Phase 3 planned

Gemphire Therapeutics (GEMP) announces plans to advance gemcabene into Phase 3 clinical development after data showed clinically meaningful reductions in LDL-C and hsCRP across multiple trials. The micro cap stock rose 13% in low volume, in after hours trade. Check out detailed news in our Daily Pharma Scoop at SeekingAlpha Marketplace.

Insiders sell $ATHX

Insider sales at Athersys, Inc. (ATHX). Pres, COO -$35,726 Exec Vice Pres, CSO -$32,508 Check out all pharma insider sales in our SeekingAlpha Marketplace Daily Pharma Scoop.